… weeks for patients in the erlotinib group versus 11·1 … treated with erlotinib (n=307) compared
with EGFR-positive patients given placebo (n=311; median PFS 12·3 weeks in the erlotinib …

… Particularly, more than 90% of the patients (15 of 16) with grade 3 skin rash achieved
stable disease or better to erlotinib treatment. Its statistical significance was retained at the …

… intensity for erlotinib and placebo in the sequential combination phase was … treatment.
Patients who did not progress during the sequential combination phase received further erlotinib (…

… glioblastoma multiforme (GBM) in a multicenter phase I trial. … treated with erlotinib for 1 week
before concurrent erlotinib … concurrent erlotinib and radiation therapy in the initial treatment …

… Based on the rationales, we hypothesized that low-dose erlotinib would be safe and …
multicenter phase 2 clinical trial to investigate the efficacy and safety of low-dose erlotinib in …

… of combining sorafenib and erlotinib with promising … This multicenter, single-arm, prospective
phase II study evaluates the clinical activity and safety of sorafenib combined with erlotinib …

… , regardless of their HER1/EGFR status, were treated with erlotinib at an initial dose of
150 mg daily. Dose reductions or escalations were allowed based on tolerability of erlotinib. …

… We compared the safety data of the erlotinib group in our study with other phase III trials in
Asian countries and the grade R3 TEAE rate for erlotinib monotherapy in our study was within …

… phase I study to incorporate erlotinib into two frequently used chemoradiotherapy regimens
(SWOG9504 18 and CALGB39801 5 ) for unresectable Stage III NSCLC. Erlotinib… of erlotinib …

… sorafenib and erlotinib in previously treated patients with advanced NSCLC. … , phase II study
to evaluate efficacy and safety of combination of sorafenib with erlotinib in previously treated…